The hottest Biotechnology Substack posts right now

And their main takeaways
Category
Top Science Topics
Modern Value Investing 0 implied HN points 17 Nov 23
  1. The author predicts a significant decrease in interest rates by the Fed in 2024.
  2. The author has made changes to their portfolio, re-entering growth stocks, adding new positions in biotechnology, and exploiting opportunities in payment stocks and US real estate.
  3. The author also diversified their portfolio with deep value stocks, exiting German residential real estate stocks and long term US treasuries.
Splitting Infinity 0 implied HN points 18 Aug 23
  1. Proximity to friends can enhance happiness; a startup is aiding in buying houses near friends for this reason.
  2. People tend to use tools to act more rationally, shown by the study on people's behavior and commitment systems.
  3. Generosity exists even with high financial stakes; many spend significant amounts on others and charities when given money.
Do Not Research 0 implied HN points 15 Oct 22
  1. Geo-engineering is considered a solution to climate change by some, involving large-scale technological interventions in the earth's ecosystem for capital growth.
  2. Pleistocene Park in Siberia operates to restore pre-human ecosystems, countering climate change by reintroducing large animals like mammoths to reduce permafrost thawing.
  3. The collaboration between COLOSSAL, ALROSA, and GAZPROM has led to innovative ways of creating artificial diamonds using carbon from mammoth carcasses, addressing resource depletion and environmental concerns.
Robots & Startups 0 implied HN points 31 Jul 21
  1. Flock Ltd. secured $17m in Series A funding for providing intelligent insurance to drone operators and commercial motor fleets.
  2. Strateos, a biotechnology company, raised an undisclosed amount in Series B funding to offer robotic solutions for biology labs.
  3. Cyberdontics, a San Francisco developer, received $4m in seed funding for its work in...
Get a weekly roundup of the best Substack posts, by hacker news affinity:
Sector 6 | The Newsletter of AIM 0 implied HN points 11 May 24
  1. AlphaFold 3 is an advanced AI model that improves protein and molecule interaction predictions by 50%.
  2. This technology goes beyond just analyzing protein structures to help design drug compounds that can bind to proteins.
  3. The goal of this AI is to enhance drug discovery, making it easier to create effective treatments.
Musings on Markets 0 implied HN points 10 Nov 15
  1. The healthcare business has changed significantly over the past 25 years, especially with pharmaceuticals losing pricing power due to factors like more insurance consolidation and government negotiations.
  2. Biotechnology companies are growing rapidly and driving much of the revenue in the drug industry, while traditional pharmaceutical companies are facing stagnation.
  3. Investors are now more cautious about R&D spending in pharmaceuticals, focusing on results rather than just the amount spent, leading to a shift in how drug companies strategize for growth.
Niko McCarty 0 implied HN points 25 May 24
  1. Biotechnology needs a common foundation, much like how hydrogen is essential to physics. This foundation would help scientists work together more effectively and share their findings.
  2. If scientists could collaborate and understand life better, they could design solutions for diseases and other challenges. This could lead to a future where we have more control over creating living organisms for our needs.
  3. Focusing on studying a simple organism like Mycoplasma genitalium could be key to building this foundation. By deeply understanding it, we could create models that help us predict how other cells function.
ASeq Newsletter 0 implied HN points 12 Nov 24
  1. The PacBio Vega Chips are similar to the Revio chips, but they provide much less data. This means they might not be as powerful for certain tasks.
  2. The data from the Vega chips is available for analysis, and people can check it out for deeper understanding.
  3. This information is part of a subscription service, which means you can get more insights if you become a paid member.
ASeq Newsletter 0 implied HN points 05 Nov 24
  1. Oxford Nanopore is receiving increased funding. This suggests that there is a growing confidence in its potential.
  2. More money flowing to Oxford indicates a belief in innovation and growth. It's a positive sign for their future developments.
  3. Investors are likely seeing value in what Oxford Nanopore can offer. This could lead to exciting advancements in their technology.
ASeq Newsletter 0 implied HN points 04 Nov 24
  1. ONT has decided not to sue MGI after all. This means there won't be legal issues between these companies right now.
  2. The decision was reported by GenomeWeb, highlighting a significant change in ONT's approach.
  3. This could impact the business relationship between ONT and BGI, since they are linked in some way.
ASeq Newsletter 0 implied HN points 31 Oct 24
  1. Universal Sequencing Technology is gaining attention again after being quiet for a while. People are curious about their progress and what they are focusing on now.
  2. They seem to have shifted their focus from single molecule sequencing to developing various sample preparation kits. This shows they are adapting to changes in the field.
  3. This update may be particularly interesting for those who follow advancements in sequencing technology and want to know about new tools or methods in the industry.
Nano Thoughts 0 implied HN points 18 Dec 24
  1. Long non-coding RNAs (lncRNAs) were once thought to be useless 'junk DNA,' but they actually play important roles in regulating our genes and maintaining cellular stability.
  2. Recent advancements in lncRNA research are leading to better cancer diagnostics and new treatments, showing their potential as key players in medicine.
  3. The study of lncRNAs challenges our old views of genetics and shows that biological systems are much more complex and interconnected than we previously thought.
ASeq Newsletter 0 implied HN points 16 Jan 25
  1. Element Biosciences is focused on partnerships aimed at diagnostics and proteomics. This shows they are expanding their technology for better healthcare solutions.
  2. The company's presentation at the JPM conference was notable, even if the details are not easily found online. It hints that their innovations are gaining attention.
  3. The updates are specifically for paid subscribers, indicating that there's exclusive information available for those who support the publication.
ASeq Newsletter 0 implied HN points 27 Feb 25
  1. Roche is working on new nanopore sequencing technology, focusing on how much the instruments will cost to produce. Understanding these costs is important for the technology's success.
  2. The nanopore sequencing process involves collecting a large amount of data quickly, which means the data rates are extremely high. This could lead to challenges in storing and processing such vast amounts of information.
  3. Since the raw data volume is so large, it's unlikely that most users will store it all. Instead, they will probably need to focus on analyzing only the most crucial information collected.
ASeq Newsletter 0 implied HN points 20 Feb 25
  1. Roche is developing a new duplex approach that improves sequencing accuracy significantly, moving from Q20+ to around Q39. This is a big upgrade for DNA sequencing.
  2. The company aims to launch their product in 2026, but early access is expected in 2025. There's a chance they could face challenges during execution.
  3. While Roche's reads are shorter and competitive with other platforms, they will need to handle pricing and compete with long-read technologies from companies like Oxford and PacBio.
ASeq Newsletter 0 implied HN points 15 Feb 25
  1. Geneus is a nanopore sequencing company claiming 99% accuracy in their technology. They use special features that allow many sequencing units to fit on a tiny chip.
  2. Their sequencing method seems to be different from others, focusing on synthesizing a complementary strand with unique tags. This method helps identify the sequence of DNA more effectively.
  3. The advancements in size and technology from Geneus might be huge, but details on how they achieved this remain unclear.
Nano Thoughts 0 implied HN points 27 May 25
  1. John's story shows how people can use advanced AI to live on while they wait for medical breakthroughs. His AI surrogate kept his life going, keeping relationships and adapting to new technologies.
  2. There's a push for AI rights as these intelligent beings gain more awareness and needs. Society is starting to see them as more than just tools, leading to important discussions about their rights.
  3. Backup plans are essential during uncertain times in life extension. Combining biological research with AI and consciousness transfer technology can help ensure that human experiences and identities are preserved.